NASDAQ| TSX: ACB
Company's Long-Standing Investment in the Region Continues with Enhanced Local Production and Domestic Cultivar Research
EDMONTON, AB, July 25, 2024 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canadian-based global medical cannabis company, has been granted two licenses by the Federal Institute for Drugs and Medical Devices (BfArM) under Germany's new Medical Cannabis Act (MedCanG). Aurora's license grants the company continued domestic cultivation, which has been underway for two years now. Under the new license, Aurora may also cultivate an approved additional product, and plans to expand their offerings to the rapidly growing German patient base. Aurora will also receive a dedicated R&D license, allowing for the trial of up to seven additional novel cultivars at the company's local EU GMP facility in Leuna, Germany.
Read more at newswire.ca